USPTO Examiner LIU SUE XU - Art Unit 1616

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18602677COMPOSITION FOR SKIN WHITENING COMPRISING CARVEDILOLMarch 2024June 2025Abandon1610NoNo
18045745DRY FORMULATIONS OF ANTI-SARS-COV-2 VIRUS ANTIBODIES AND COMPOSITIONS AND METHODS OF USE THEREOFOctober 2022June 2025Abandon3210NoNo
17934626PAIN RELIEF SALVE AND A METHOD FOR MAKING SUCHSeptember 2022May 2025Abandon3210NoNo
17513384COMPOSITION AND METHOD FOR STIMULATING PLANT GROWTH AND PRODUCTIVITYOctober 2021April 2025Abandon4210NoNo
17363593Antimicrobial Compositions and Uses ThereofJune 2021July 2022Abandon1311NoNo
17323109PHARMACEUTICAL FORMULATION CONTAINING REMDESIVIR AND ITS ACTIVE METABOLITES FOR DRY POWDER INHALATIONMay 2021November 2022Abandon1811NoNo
16944800Flumioxazin CompositionsJuly 2020November 2022Abandon2710NoNo
16765148NOVEL OPHTHALMIC COMPOSITION AND METHODS OF USEMay 2020July 2022Abandon2610NoNo
16865882PHOTOPROTECTIVE COMPOSITIONS COMPRISING AN AQUEOUS PHASE AND A LOW MELTING POINT APOLAR WAXMay 2020September 2022Abandon2801NoNo
16799042MICROALGAE EXTRACT FOR AGRICULTURAL USEFebruary 2020May 2022Abandon2710NoNo
16624854COMPOSITION FOR STABILIZING AT LEAST ONE AGROCHEMICAL ACTIVE INGREDIENTDecember 2019May 2022Abandon2801NoNo
16613345SEED, SOIL, AND PLANT TREATMENT COMPOSITIONSNovember 2019May 2022Abandon3021NoNo
16611798Use Of N-Alkyl Glucamides For Reducing Drift During The Application Of Glufosinate-Containing Plant Treatment AgentsNovember 2019May 2022Abandon3011NoNo
16468256ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING AN UNMICRONIZED SELECTIVE PROGESTERONE RECEPTOR AS ACTIVE AGENTJune 2019April 2022Abandon3411NoNo
16319065GRACILARIA BASED COMPOSITIONS FOR PLANTS AND METHODS OF APPLICATIONJanuary 2019September 2022Abandon4401NoNo
16313283PYRIDINE-BASED COMPOUND INCLUDING ISOXAZOLINE RING AND USE THEREOF AS HERBICIDEDecember 2018July 2022Abandon4321NoNo
16192337UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATIONNovember 2018June 2022Abandon4341YesNo
16179623LOW ERUCTATION COMPOSITION AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE IN A SUBJECT WITH FISH ALLERGY/HYPERSENSITIVITYNovember 2018May 2022Abandon4221NoNo
16080758NETWORKED DISPERSION OF BIOCELLULOSE MICROFIBRILS IN WATERAugust 2018September 2022Abandon4941YesNo
15949956FORMULATION FOR TOPICAL WOUND TREATMENTApril 2018May 2019Abandon1420NoNo
15923095Sustained Release Cannabinoid FormulationsMarch 2018July 2022Abandon5221NoNo
15834805CORE STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOFDecember 2017September 2022Abandon5770NoNo
15577176ZINC OXIDE-CONTAINING COMPOSITE PARTICLE, ULTRAVIOLET-SHIELDING COMPOSITION, AND COSMETICNovember 2017June 2022Abandon5540YesNo
15802405COATING-TYPE CONTACT MEDIUM FOR ULTRASOUND DIAGNOSISNovember 2017July 2020Abandon3220YesNo
15794534METHOD FOR STIMULATION OF SEEDSOctober 2017January 2020Allow2720YesNo
15700405TRANSDERMAL PREPARATIONSeptember 2017March 2019Abandon1810NoNo
15550546USE OF A COMBINATION OF TAURINE OR A DERIVATIVE THEREOF, BIOTIN AND GRAPE EXTRACT FOR COMBATING FINE HAIRAugust 2017June 2022Abandon5840YesNo
156725563D Ti-6Al-4V Structures with Hydrogel MatrixAugust 2017September 2022Abandon6050NoNo
15548616PROCESS FOR GRANULATING SEVELAMER CARBONATEAugust 2017April 2019Abandon2120NoNo
15535326AGENT FOR HYPODERMIC INJECTIONS AND PRODUCTION METHOD FOR SYRINGES CONTAINING AGENT FOR HYPODERMIC INJECTIONSJune 2017March 2019Abandon2120NoNo
15486418COMPOSITIONS AND KITS FOR COMPOUNDING PHARMACEUTICALSApril 2017March 2019Abandon2311NoNo
15475114METHOD FOR PREPARING NOBLE METAL NANOPARTICLES FROM MYRRHMarch 2017May 2021Abandon4940NoYes
15429066Sun protection towelettesFebruary 2017March 2019Abandon2510NoNo
15328406SYSTEM FOR THE IMMEDIATE RELEASE OF ACTIVE AGENTSJanuary 2017June 2022Abandon6041NoNo
15326016METHODS AND RELATED COMPOSITIONS FOR IMPROVED DRUG BIOAVAILABILITY AND DISEASE TREATMENTJanuary 2017July 2019Abandon3021NoNo
15336764COMBINATION OF NATURAL SUBSTANCES COMPRISING AT LEAST ONE GLYCYRRHETINIC ACID AND AT LEAST ONE GUGGULSTERONE, AND USE THEREOF FOR COSMETIC APPLICATIONSOctober 2016March 2019Abandon2910NoNo
15300736COMPOSITION COMPRISING EXTRACT OF ALPINE WORMWOODSeptember 2016August 2019Abandon3520NoNo
15236897Herbicide And Method Of Applying A HerbicideAugust 2016February 2021Abandon5420NoYes
15138882PROCESS FOR PREPARING WATER DISPERSIONS CONTAINING HIGH CONCENTRATION OF NANO/SUBMICRON, HYDROPHOBIC, FUNCTIONAL COMPOUNDS AND WATER DISPERSIONS OBTAINABLE THEREFROMApril 2016July 2019Abandon3931YesNo
15136379COMPOSITION COMPRISING AN ACTIVE INGREDIENT COMPOSITION AND AN ADDITIVE COMPOSITION FOR PENETRATING A TIMBERApril 2016August 2020Abandon5202YesNo
15065017COMPOSITIONS AND METHODS RELATING TO REDUCED MUCOADHESIONMarch 2016August 2019Abandon4131YesNo
11913160Compositions and Methods for Treating MicroorganismNovember 2015September 2016Abandon6011YesNo
14848399ROSEOBACTICIDES AND USES THEREOFSeptember 2015May 2017Abandon2010NoNo
14837418PESTICIDAL COMPOSITIONSAugust 2015May 2017Abandon2010NoNo
14799895COMPOSITIONS AND METHODS FOR PREVENTING OR REDUCING RESISTANCE OF INSECTS TO INSECTICIDESJuly 2015April 2017Abandon2110NoNo
14792826METHOD AND SYSTEM FOR EXTRACTING AND USING MOOMIYO COMPOSITIONSJuly 2015July 2017Abandon2521YesNo
14739053TOPOGRAPHICAL GEOMETRICAL MATRICES AND USES THEREOFJune 2015June 2021Abandon6070NoYes
14647837USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYLETHYNYL)-BICYCLOALKANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESSMay 2015May 2017Abandon2301NoNo
14647852USE OF SUBSTITUTED 1-(ARYL ETHYNYL)-, 1-(HETEROARYL ETHYNYL)-, 1-(HETEROCYCLYL ETHYNYL)- AND 1-(CYCLOALKENYL ETHYNYL)-CYCLOHEXANOLS AS ACTIVE AGENTS AGAINST ABIOTIC PLANT STRESSMay 2015May 2017Abandon2301NoNo
14656406TRANSDERMAL CANNABINOID PATCHMarch 2015March 2019Abandon4840NoNo
14639043LIGHT PROTECTING COMPOSITION WITH REDUCED TOTAL AMOUNT OF UV FILTER CONTAINING A POLYSILOXANE-BASED UV FILTERMarch 2015June 2020Abandon6041NoYes
14424256USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESSFebruary 2015January 2017Abandon2310NoNo
14424260USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESSFebruary 2015February 2017Abandon2410NoNo
14424284USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESSFebruary 2015February 2017Abandon2410NoNo
14587554CONJUGATES COMPRISING AN N-OXIME BOND AND ASSOCIATED METHODSDecember 2014January 2017Abandon2510NoNo
14412176COMPOSITIONS COMPRISING SULFORAPHANE OR A SULFORAPHANE PRECURSOR AND A MILK THISTLE EXTRACT OR POWDERDecember 2014May 2018Abandon4140YesYes
14576807NATURAL OIL METATHESIS COMPOSITIONSDecember 2014March 2019Abandon5130NoNo
14564726Enteric-Coated Functional Food Ingredients And Methods For Making The Enteric-Coated Functional Food IngredientsDecember 2014October 2020Abandon6050NoNo
14406275CROP ENHANCEMENTDecember 2014January 2017Abandon2620NoNo
14527812HYDROPHILIZATION POLYMERS AND METHODS FOR USEOctober 2014January 2017Abandon2710NoNo
14395396SILK FIBROIN-BASED PERSONAL CARE COMPOSITIONSOctober 2014May 2022Abandon6061YesYes
14513306POLYURETHANE DISPERSIONS FOR SEALING THE TEATS OF THE MAMMARY GLANDS IN MILKING ANIMALSOctober 2014March 2019Abandon5320YesYes
14513994NANOPARTICLE PEG MODIFICATION WITH H-PHOSPHONATESOctober 2014December 2016Abandon2611NoNo
14469846COMPOSITIONS FOR IMPROVED TISSUE OXYGENATION BY PERITONEAL VENTILATIONAugust 2014February 2020Allow6060YesNo
14452663DEODORIZING AND SKIN CLEANINGAugust 2014September 2019Abandon6090YesNo
14307438Antiperspirant Spray Devices and CompositionsJune 2014March 2019Abandon5760NoNo
14307433Antiperspirant Spray Devices and CompositionsJune 2014March 2019Abandon5760NoNo
14355905Hydrophilic OrganosilanesMay 2014March 2019Abandon5960YesNo
14355246OIL-IN-WATER TYPE EMULSIFIED SUNSCREEN COSMETICApril 2014September 2019Abandon6060NoYes
14109976Antimicrobial Ophthalmic DevicesDecember 2013November 2019Abandon6030NoYes
14124604INHIBITION OF FATTY ACID AND CHOLESTEROL UPTAKE BY CARBON MONOXIDE (CO)December 2013August 2015Allow2040NoNo
14115276Compositions Comprising Siloxane PolymerNovember 2013March 2019Abandon6031NoYes
13992946Dosage FormAugust 2013January 2020Abandon6061NoYes
13975606DROPPER DEVICE FOR CONTROLLED DISTRIBUTION OF A MAKE-UP PRODUCTAugust 2013April 2019Abandon6061YesNo
13773016Modafinil FormulationsFebruary 2013April 2014Abandon1410NoNo
13695646DELAYED RELEASE ORAL DISINTEGRATING PHARMACEUTICAL COMPOSITIONS OF LANSOPRAZOLEDecember 2012July 2019Abandon6080YesNo
13383067Peracid/Peroxide Composition, Process for Accurately Making the Same, and Method for Use as an Evaporating Film Anti-Microbial Solution and as a PhotosensitizerNovember 2012May 2015Abandon4121NoYes
13494848SYNCHRONIZED WATER AND PRODUCTION AND USE THEREOFJune 2012October 2020Abandon6060YesYes
13510126POLYETHYLENE GLYCOL CONTAINING COMPOSITION FOR SHAVINGMay 2012April 2019Abandon6061NoYes
13379486ORAL DOSAGE FORMSMarch 2012July 2020Abandon6060NoYes
13401519METHOD FOR TREATING AIRWAY HYPER-RESPONSIVENESS WITH LIPOXIN ANALOGSFebruary 2012February 2014Abandon2410NoNo
13312143COMPOSITIONS AND METHODS FOR DELIVERY OF SOLUTION TO THE SKINDecember 2011February 2014Abandon2710NoNo
13126639USE OF HELIUM-OXYGEN GAS MIXTURES FOR TREATING PULMONARY ARTERIAL HYPERTENSIONJuly 2011February 2014Abandon3401NoNo
13125316ANTIPERSPIRANT PREPARATIONS COMPRISING HYDROTALCITEMay 2011July 2019Abandon6041YesYes
13099426Delivery of estrogen and bioequivalents thereof via the pulmonary tractMay 2011April 2014Abandon3610NoNo
13080034Clear or Translucent CompositionApril 2011July 2019Abandon60120NoNo
12933546Process Of Making A Stable Aqueous Dispersion Of Concentrated, Finely Divided Particles Of A BiocideDecember 2010February 2014Abandon4111NoNo
12865607TREATMENT OF ADENOCARCINOMA EXPRESSING LKB1 WITH MTOR INHIBITOR IN COMBINATION WITH COX2 INHIBITORDecember 2010February 2014Abandon4341NoNo
12895936Compositions and Methods for Enhancing EyelashesOctober 2010May 2022Abandon6090NoNo
12934286FORMULATION WITH REDUCED HYGROSCOPICITYSeptember 2010October 2016Abandon6030NoYes
12740116USE OF ZERO-ORDER DIFFRACTIVE PIGMENTSSeptember 2010June 2017Abandon6031YesYes
12920506Cosmetic Compositions For Imparting Superhydrophobic FilmsSeptember 2010April 2019Abandon60121NoNo
11573112Controlled-Release Agricultural Chemical FormulationApril 2007January 2019Abandon60111YesYes
11482761Photoprotective compositions comprising an aqueous phase and a low melting point apolar waxJuly 2006November 2023Abandon60141YesYes
10254707SUSTAINED RELEASE RANOLAZINE FORMULATIONSSeptember 2002December 2002Allow300NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner LIU, SUE XU.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
17
Examiner Affirmed
16
(94.1%)
Examiner Reversed
1
(5.9%)
Reversal Percentile
20.5%
Lower than average

What This Means

With a 5.9% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
25
Allowed After Appeal Filing
0
(0.0%)
Not Allowed After Appeal Filing
25
(100.0%)
Filing Benefit Percentile
0.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner LIU, SUE XU - Prosecution Strategy Guide

Executive Summary

Examiner LIU, SUE XU works in Art Unit 1616 and has examined 94 patent applications in our dataset. With an allowance rate of 4.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.

Allowance Patterns

Examiner LIU, SUE XU's allowance rate of 4.3% places them in the 0% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by LIU, SUE XU receive 3.14 office actions before reaching final disposition. This places the examiner in the 97% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by LIU, SUE XU is 41 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +5.5% benefit to allowance rate for applications examined by LIU, SUE XU. This interview benefit is in the 31% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 0.6% of applications are subsequently allowed. This success rate is in the 0% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 5.1% of cases where such amendments are filed. This entry rate is in the 2% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 5.6% of appeals filed. This is in the 1% percentile among all examiners. Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 88.9% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.